CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 277 filers reported holding CLOVIS ONCOLOGY INC in Q2 2017. The put-call ratio across all filers is 0.51 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2018 | $2,298,000 | -17.1% | 50,541 | -3.7% | 0.16% | -23.3% |
Q1 2018 | $2,772,000 | +269.6% | 52,500 | +775.0% | 0.20% | +648.1% |
Q4 2017 | $750,000 | -95.7% | 6,000 | -97.2% | 0.03% | -97.5% |
Q3 2017 | $17,457,000 | +32.7% | 211,851 | +50.7% | 1.10% | +39.1% |
Q2 2017 | $13,160,000 | +350.4% | 140,558 | +206.2% | 0.79% | +282.6% |
Q1 2017 | $2,922,000 | – | 45,900 | – | 0.21% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Palo Alto Investors LP | 3,402,781 | $231,389,000 | 9.96% |
Versant Venture Management, LLC | 101,855 | $6,926,140,000 | 7.29% |
Avoro Capital Advisors LLC | 1,102,884 | $74,996,000 | 4.86% |
Redmile Group, LLC | 1,320,027 | $89,762,000 | 3.90% |
NEXTHERA CAPITAL LP | 233,200 | $15,858,000 | 2.92% |
Iguana Healthcare Management, LLC | 60,000 | $4,080,000 | 2.66% |
HealthCor Management, L.P. | 973,840 | $66,221,000 | 2.16% |
Casdin Capital, LLC | 127,500 | $8,670,000 | 2.11% |
Prosight Management, LP | 40,000 | $2,720,000 | 2.00% |
Camber Capital Management LP | 600,000 | $40,800,000 | 2.00% |